Abstract: FR-PO1109
Despite Vaccination, Risk of COVID-19 Outcomes Is Elevated in Patients with ESRD: Initial Results from INFORM Retrospective Study in England using National Health Service Datasets
Session Information
- COVID-19 - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Dube, Sabada, Epidemiology, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, United Kingdom
- Lu, Yi, Real-World Evidence, Data Analytics, Evidera, London, United Kingdom
- McNulty, Richard J., Medical Affairs, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, United Kingdom
- Graham, Sophie, Real-World Evidence, Data Analytics, Evidera, London, United Kingdom
- Arnetorp, Sofie, Health Economics and Payer Evidence, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Justo, Nahila, Real-World Evidence, Data Analytics, Evidera, Stockholm, Sweden
- Yokota, Renata, P95, Leuven, Belgium
- Evans, Kathryn, Real-World Evidence, Data Analytics, Evidera, Waltham, Massachusetts, United States
- Carty, Lucy, Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
- Yates, Mark, Real-World Evidence, Data Analytics, Evidera, London, United Kingdom
- Taylor, Sylvia, Medical Evidence, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, United Kingdom
- Quint, Jennifer Kathleen, National Heart and Lung Institute, Imperial College London, London, United Kingdom
Background
Patients (pts) with end-stage renal disease (ESRD) are considered immunocompromised. However, pre-exposure prophylaxis (PrEP) is not always recommended in this population. We report initial results from the INFORM retrospective study on severe COVID-19 outcomes in fully vaccinated (≥3 doses) pts with ESRD or dialysis (ESRD or D) and ESRD with dialysis (ESRD+D).
Methods
COVID-19–related hospitalizations and deaths in pts aged ≥12 years in England were identified from a random sample of 25% of pts in National Health Services datasets (Jan 1, 2022–Dec 31, 2022). Incidence rates (IRs) per 100 person years (PY) were determined in pts with ESRD or D and with ESRD+D. Incidence rate ratios (IRRs) per 100 PY (crude and adjusted for age and sex) were calculated for pts with ESRD or D and ESRD+D versus those without.
Results
Pts with ESRD or D or with ESRD+D had higher IRs for COVID-19–related hospitalizations or deaths than those without. Adjusted IRRs for hospitalization and mortality were higher in pts with ESRD or D and ESRD+D than those without. Hospitalization adjusted IRRs for pts with ESRD or D and ESRD+D were 5.59 (95% CI 5.07–6.16) and 9.91 (95% CI 8.69–11.30), respectively (Table). Mortality adjusted IRRs for pts with ESRD or D and ESRD+D were 5.04 (95% CI 4.11–6.16) and 8.68 (95% CI 6.41–11.77), respectively (Table).
Conclusion
Despite full COVID-19 vaccination, including boosters, pts with ESRD or D and ESRD+D are at greater risk of severe COVID-19 outcomes than those without. Therefore, vaccinated pts with ESRD may benefit from PrEP to reduce the risk of severe COVID-19.
Funding
- Commercial Support – AstraZeneca